Genetically Modified Neural Stem Cell Lines
Genetically modified neural stem cell (NSC) lines serve as a pivotal model for investigating the pathophysiology of various brain tumors, including glioblastomas and medulloblastomas. Alfa Cytology offers comprehensive services for the development of genetically modified NSC lines specifically designed for brain tumors.
Introduction to Genetically Modified NSC Lines Model
Neural stem cells (NSCs) are cells that are capable of self-renewal and have the potential to differentiate into neurons, astrocytes, oligodendrocytes, and many other differentiation potentials. During development, NSCs are present in the neural tube and then gradually enter the subventricular zone, striatum, and hippocampus. Throughout the life cycle, new neurons are constantly produced. When the brain is damaged, some dormant NSCs will be activated.
Our Services
Alfa Cytology offers genetically modified neural stem cell lines, which are genetically engineered to genetically modify neural stem cells to stably express specific exogenous genes, such as fluorescent proteins, neurotransmitter probes, calcium probes, and light-sensitive proteins. This enables real-time observation and precise manipulation of the cells, which can be applied to a variety of brain science research fields such as electrophysiology, optogenetics, and neural circuit tracing. Meanwhile, we can provide a neural stem cell-directed differentiation medium, which can differentiate neural stem cells into neural cell types of interest, providing customers with more convenient experimental conditions and improving the reproducibility of experiments.
Neurotransmitter probe neural stem cell lines
We use probes that can accurately detect neurotransmitter dynamics in real-time with high sensitivity, specificity, and resolution, and can be used to resolve complex functions of the nervous system at high temporal and spatial scales.
Calcium probe neural stem cell lines
We convert changes in calcium concentration into fluorescent signals using indicators that can sense Ca2+ concentration and provide you with a wide range of Ca2+ probe-based neural stem cell development and related products as a biotherapeutic approach to help you in your pioneering exploration in the field of brain tumors.
Voltage probe neural stem cell lines
We seek to develop voltage probe-like neural stem cell lines by combining nanoparticles or fluorescent molecular probes that are sensitive to changes in cell membrane potential and have high signal-to-noise ratios, thereby enabling in vivo detection of electrical activity in large clusters of neurons with high spatiotemporal resolution.
Optogenetic neural stem cell lines
We integrate optogenetic technology with electrophysiological and molecular biology techniques to provide you with optogenetic-based neural stem cell development services for the direct demonstration of behavioral outcomes exhibited by neuronal activation.
Chemical genetic neural stem cell lines
We modify the GPCR on the nerve cell membrane to obtain DREADDs, which are unable to bind the original neurotransmitter ligand, and control the cellular activity by adding or removing the specified drugs, thus allowing you to observe the different excitability changes in the nerve cells triggered by different drugs.
Case Study - Genetically Modified Neuroepithelial Stem Cell Model
Model Introduction
Genetically modified neuroepithelial stem (NES) cell models offer a versatile, isogenic platform for preclinical oncology research. By enabling direct comparison between normal and malignant neural stem cells from a common genetic background, this system supports high-throughput drug screening and the identification of tumor-selective vulnerabilities, facilitating the development of targeted therapies that spare healthy neural tissue.
Model Information
- Model: Genetically Modified Neuroepithelial Stem (NES) Cell Model
- Genetic Background: Patient-derived, featuring germline PTCH1 mutation
- Cancer Type: Sonic Hedgehog Medulloblastoma (SHH-MB)
- Key Modification: In vivo passaging to generate isogenic tumor-derived NES cells
Model Construction
This model is established through a stepwise process starting with patient-derived somatic cells, which are reprogrammed into induced pluripotent stem cells and subsequently differentiated into non-tumorigenic neuroepithelial stem cells. These normal NES cells are then subjected to serial orthotopic transplantation in immunocompromised mice, enabling in vivo selection and malignant transformation. Tumor cells isolated from successive transplantations give rise to highly tumorigenic NES cells that retain the original patient's genetic background.
Fig. 1 Schematic overview of the neuroepithelial stem (NES) cell model establishment. (Source: Alfa Cytology)
Model Data
- High-Throughput Screening Capability: The isogenic NES model enables parallel assessment of compound efficacy on normal and malignant cells. Differential drug sensitivity scores quantify tumor selectivity, allowing prioritization of candidates with favorable therapeutic windows.
- Identification of Selective Vulnerability: S6K1 inhibition demonstrates preferential cytotoxicity against SHH-MB tumor cells, impairing spheroid formation and self-renewal capacity with minimal effects on normal neural stem cells or differentiated neurons.
- In Vivo Validation: Genetic knockdown of S6K1 in subcutaneous and orthotopic xenograft models significantly reduces tumor growth and proliferation while extending survival, confirming S6K1 as a functional dependency in SHH-MB.
Fig. 2 S6K1 knockdown impairs tumor growth in subcutaneous and orthotopic xenograft models. Data are expressed as mean ± SEM. (Source: Alfa Cytology)
Alfa Cytology's technical services and products on genetically modified neural stem cells are still being iteratively updated. For more information, please feel free to contact us to customize your needs.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
